AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00579371 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Islets of Langerhans
Description: Subjects will receive islets isolated from one donor pancreas per transplantation event. Subjects will receive a cumulative dose of 8,000IE/kg. Islets will be infused intraportally. If necessary, additional transplantation events will be performed.
Study NCT01997736 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ablation
Study NCT01106170 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Provex CV
Description: dietary supplement, 2 capsules per day by mouth
Study NCT01106170 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: placebo
Description: corn starch, 2 capsules per day by mouth
Study NCT04016480 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High Flow Nasal Cannula
Description: High Flow Nasal Cannula will be set at 60 liters per minute of air/oxygen admixture to reach a peripheral oxygen saturation equal or greater than 94%
Study NCT04016480 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Oxygen Therapy
Description: Conventional Oxygen Therapy will be administered through nasal cannula with a oxygen flow set to achieve a peripheral oxygen saturation equal or greater than 94%
Study NCT02817321 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: single-injection TPVB + continuous TPVB
Description: Inject local anesthetics in the T8 paravertebral space followed with catheter insertion and continuous local infusion.
Study NCT02817321 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Philip CX50 Ultrasound Scanner
Description: The curved (C1-5) probe of Philip CX 50 Ultrasound Scanner is used for scanning
Study NCT02817321 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PAJUNK Contiplex S Catheter
Study NCT02817321 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: single dose ropivacaine
Description: * 2mg/kg ropivacaine in saline with 1:200,000 adrenaline, 25ml in total~* given immediately after the correct position of the tip of the needle has been confirmed
Study NCT02817321 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: continuously infusion of ropivacaine
Description: * 0.2% ropivacaine, pulse dosadge: 0.125ml/kg/pulse, 1pulse/h at a rate of 6ml/minutes~* given through the catheter inserted in the T8 paravertebral space following the single dose
Study NCT02817321 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine given as IPCA
Description: bolus: 2mg, lock time: 10min, 1h limitation: 8mg
Study NCT02817321 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine given as IPCA
Description: bolus: 2mg, lock time: 10min, 1h limitation: 8mg
Study NCT00518154 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyridostigmine tablets
Description: Patients will take 30mg tid PO for 12 weeks
Study NCT01468584 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MP-424 (generic name:Telaprevir)
Description: 750mg q8h for 12 weeks
Study NCT01468584 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: 400 - 1000 mg/day based on body weight for 24 weeks
Study NCT01468584 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2b
Description: 1.5mcg/kg/week for 24 weeks
Study NCT02816307 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: blood samples
Study NCT02601521 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internal tobacco coach
Description: The internal coaching program will provide cognitive-behavioral counseling and medication adherence support for smokers who are ready to quit in the next 3 months It consists of:~1. Telephone counseling by the Tobacco Coach (8 calls over 12 weeks). supplemented by automated phone calls using interactive voice response. At each IVR contact, smokers can request a call back from the Tobacco Coach. Smokers who are not quit after 3 months can restart into the 12-week counseling program.~2. The Tobacco Coach will assist smokers in choosing pharmacotherapy and in obtaining a prescription from the smoker's physician.~3. Support and monitoring for 12 months using automated phone calls. If relapse occurs, the smoker will have the option to return to the active 12-week program.
Study NCT02601521 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: External tobacco coach
Description: Referral to Massachusetts Smokers Helpline (telephone quitline operated by the Massachusetts Tobacco Control Program) for proactive telephone counseling.
Study NCT03168880 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel + Carboplatin
Description: Platinum based chemotherapy against the standard taxane based chemotherapy in the neo- adjuvant setting
Study NCT03168880 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel only
Study NCT03548935 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: Participants will receive semaglutide subcutaneous (s.c.; under the skin) injection(s) once-weekly as well as diet and physical activity counselling for 68 weeks. Dose escalation of semaglutide will take place as follows: 0.25 mg from week 1 to 4, 0.5 mg from week 5 to 8, 1.0 mg from week 9 to 12, 1.7 mg from week 13 to 16 and 2.4 mg from week 17 to week 68.
Study NCT03548935 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (semaglutide)
Description: Participants will receive semaglutide matching placebo s.c. injection(s) once-weekly as well as diet and physical activity counselling for 68 weeks.
Study NCT04536688 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RGLS4326
Description: Solution for subcutaneous injection
Study NCT01324258 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1120212
Description: Part1 and Part2
Study NCT01324258 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Part2
Study NCT01074190 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Group 1
Description: A basal infusion rate for the PCEA will be set at 8 mL/h with patient administered boluses of 8 mL every 10 minutes and a one hour limit of 32 mL. Breakthrough pain in all groups will be managed using anesthesiologist administered boluses of bupivacaine 1.25 mg/mL without fentanyl.
Study NCT01074190 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Group 2
Description: A basal infusion rate for the PCEA will be set at 8 mL/h with patient administered boluses of 8 mL every 10 minutes and a one hour limit of 32 mL. Breakthrough pain in all groups will be managed using anesthesiologist administered boluses of bupivacaine 1.25 mg/mL without fentanyl.
Study NCT01074190 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Group 3
Description: A basal infusion rate for the PCEA will be set at 8 mL/h with patient administered boluses of 8 mL every 10 minutes and a one hour limit of 32 mL. Breakthrough pain in all groups will be managed using anesthesiologist administered boluses of bupivacaine 1.25 mg/mL without fentanyl.
Study NCT02474732 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Beactive(r) Brace
Description: Determine if the subjects are able to understand and follow the directions to apply the Beactive Brace.
Study NCT03641066 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ankle Brace
Description: Each participant will complete the 1 minute walking and 2 minute running under 5 conditions \[1\] un-braced, \[2\] Active Ankle 329 Ankle Sleeve, \[3\] AS1Pro (a lace-up brace), \[4\] Eclipse 1 (single-upright brace), and \[5\] Eclipse 2 (double upright brace)
Study NCT00976222 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: intravitreal injection with ranibizumab
Description: 0.5 mg in 0.05 ml, monthly, 12 months
Study NCT06330389 — intervention group
Intervention type: PROCEDURE
Intervention: Burn Injuries Graft Surgery
Description: Burn Injuries Graft Surgery
Study NCT01628588 — intervention group
Intervention type: DRUG
Intervention: bimatoprost 0.01%
Description: Patients with POAG or OHT prescribed Lumigan® (bimatoprost 0.01%) treatment in a dose determined by the physician prior to study entry
Study NCT02912572 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Avelumab will be administered intravenously twice per cycle Each Cycle lasts 28 days Premedication Antihistamine and Paracetamol will be administered prior to treatment
Study NCT02912572 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talazoparib
Description: Talazoparib will be taken one time per day by mouth Each Cycle lasts 28 days
Study NCT02912572 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axitinib
Description: Axitinib will be taken twice per day by mouth Each Cycle lasts 28 days
Study NCT01970995 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: THS 2.2 Menthol (mTHS 2.2)
Description: THS 2.2 Menthol ad libitum for 5 days in confinement prolonged by 85 days in an ambulatory setting
Study NCT01970995 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Smoking Abstinence (SA)
Description: SA for 5 days in confinement prolonged by 85 days in an ambulatory setting
Study NCT01970995 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Menthol Conventional Cigarette (mCC)
Description: Subject's own preferred brand of mCC ad libitum for 5 days in confinement prolonged by 85 days in an ambulatory setting
Study NCT01698164 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: estradiol plus MPA
Description: Participants are given estradiol and synthetic progestin.
Study NCT01698164 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ximingting Tablet
Description: Participants are given phytoestrogen.
Study NCT01698164 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: estradiol plus progesterone
Description: Participants are given estradiol and natural progesterone.
Study NCT01923597 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Green tea extract
Description: 200mg/capsule Administered orally 4 capsules per day For 3 months
Study NCT01923597 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Green tea extract
Description: 200mg/capsule Administered orally 4 capsules per day For 3 months
Study NCT03001050 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: PINPOINT System
Description: To use the camera probe and identify the tendon and footprint vascularity at the time of surgery
Study NCT00482430 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: MK0557
Description: MK0557 10mg tablet qd for a 15-wk treatment period
Study NCT00482430 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Comparator: Placebo (unspecified)
Description: MK0557 Pbo tablet qd for a 15-wk treatment period
Study NCT02919878 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Nucleoside analog- Chemotherapy
Study NCT02919878 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: XRT
Description: pre-operative radiotherapy given concurrently with Gemcitabine chemotherapy
Study NCT02919878 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: Capecitabine is given post operatively as adjuvant chemotherapy for 6 cycles. Each cycle consist of 2500 mg/m2 per day given orally from D1-14
Study NCT00390754 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education for pregnancy planning
Description: Provision of free home pregnancy tests to women at risk for unintended pregnancy
Study NCT01576549 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2127399
Description: Administered subcutaneously
Study NCT01319695 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: corifollitropin alfa
Description: 100 microg for a group of women weighing \<or=60 kg and 150 microg for a group of women weighing >60 kg
Study NCT01319695 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: recombinant follicle stimulating hormone (FSH)
Description: 150-300 IU of the drug daily from day 2 of the menstrual cycle until more than 2 follicles are >18mm
Study NCT03150771 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Description: Injection
Study NCT03656861 — intervention group
Intervention type: OTHER
Intervention: Physical load
Description: The impact of training on cardiac structure and function depends on the type, intensity and duration of the activity, as well as previous physical activity engagement, genetics and gender type. More knowledge about cardiac pathophysiologic training adaptation is needed.
Study NCT02170285 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Interventional TDCS
Description: The primary intervention will be cathodal (inhibitory) tDCS over non-lesioned M1. This will be targeted using TMS baseline mapping data and neuronavigation (Brainsight2, Rogue Research, Montreal) individualized to the subjects MRI. Soft, replaceable 25cm2 electrodes will be placed over clean, dry scalp with the cathode over marked M1 and the reference electrode over contralateral forehead/orbit consistent with standard protocols. The current-controlled DC stimulator (neuroConn GmbH, Ilmenau, GE) will be turned up slowly over 30 seconds to the treatment current of 1.0 mA. TDCS will be administered each day during the first 20 minutes of the 90 minute therapy session. Child, family, and both treating and measuring occupational therapists are blinded to treatment allocation.
Study NCT02170285 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham TDCS
Description: Sham subjects will undergo exactly the same tDCS protocol as outlined above. This includes the initial stimulation sequence, generating the initial transient scalp sensations identical to the treatment group. The stimulator will be programmed by the technologist to automatically ramp down to off over 30 seconds after 120 seconds of stimulation.
Study NCT02779374 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Autologous bone marrow transplantation
Description: Bone marrow aspiration of 10 ml/kg is done from the posterior iliac crest. The sample is put in sterile container with appropriate amount of heparin then filtered to remove bone spicules, fat, and cellular debris. The filtered sample is injected unprocessed in a peripheral vein. The process is done once.
Study NCT01741649 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Clorhexidine
Description: Cleaning of the surgical site previous to the incision with a clorhexidine solution for five minutes.
Study NCT01741649 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Povidone
Description: Cleaning of the surgical site previous to the incision with a povidone solution for five minutes.
Study NCT04081363 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Centanafadine
Description: Extended-release and immediate-release capsules.
Study NCT04362280 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ReCHARGE
Description: During their PE class, all participants (both arms) participate in an intensive lifestyle intervention with established efficacy among this population for the academic fall semester. The following semester, participants are randomized to different treatment arms. ReCHARGE increases the intensity of treatment provided in the first semester by increasing social support and addressing common barriers youth have to adhering to intervention.
Study NCT04362280 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: TAU
Description: PE class as usual led by PE teacher.
Study NCT02043535 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Delivery of precise levels of carbon dioxide with the RA-MR™ Virtual Sequential Gas Delivery System.
Description: All participants will undergo a baseline rest Rb-82 positron emission tomography (PET) myocardial perfusion imaging scan (MPI) with low-dose computed tomography. Following this baseline study, serial Rb-82 PET MPI using a target level of carbon dioxide (CO2) (approximately 60 mmHg (± 3 mmHg)) as a stress agent will be performed. The 60 mmHg level will be repeated following a minimum 10 minute rest. A rest/stress Rb-82 PET MPI will be performed after return to normal CO2 levels (normocapnea) using persantine as the stress agent.~Myocardial perfusion stress testing
Study NCT02043535 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Delivery of rubidium radioisotope (Rb-82) using the automated pump/elution system
Description: All participants will undergo a baseline rest Rb-82 positron emission tomography myocardial perfusion imaging scan (PET MPI) with low-dose CT. Following this baseline study, serial Rb-82 PET MPI using three target levels of pulmonary end-tidal carbon dioxide tension (PetCO2) (approximately 60 mmHg (± 3 mmHg)) as a stress agent will be performed. The 60 mmHg level will be repeated following a minimum 10 minute rest. A second rest Rb-82 PET MPI will be performed after return to normocapnea, followed by a pharmacologic persantine stress Rb-82 PET MPI.
Study NCT00371293 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Weight Loss Program
Description: Participants in the weight loss program will receive weekly dietary counseling and will be encouraged to decrease caloric intake and increase physical activity.
Study NCT00371293 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight Loss Program
Description: Participants in the weight loss program will receive weekly dietary counseling and will be encouraged to decrease caloric intake and increase physical activity.
Study NCT00371293 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CPAP therapy
Description: Participants receiving CPAP therapy will use a CPAP machine each night while they sleep.
Study NCT00371293 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP therapy
Description: Participants receiving CPAP therapy will use a CPAP machine each night while they sleep.
Study NCT01121133 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: navitoclax
Description: Subjects will be dosed with Navitoclax, then dosed with Navitoclax in combination with Rifampin.
Study NCT01121133 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin
Description: Subjects will be dosed with Navitoclax, then, dosed with Navitoclax in combination with Rifampin.
Study NCT02234154 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: TOPS System
Description: Non-randomized study involving implantation of a TOPS via lumbar surgery to decompress and provide stability to the index level.
Study NCT04231149 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Test product 2
Description: Test catheter 2
Study NCT04231149 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test product 2
Description: Test catheter 2
Study NCT04231149 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Test product 3
Description: Test catheter 3
Study NCT04231149 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test product 3
Description: Test catheter 3
Study NCT04231149 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Comparator
Description: SpeediCath Flex
Study NCT02060578 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Questionnaire and interview
Description: Questionnaire completed by the parents Interview with the parents and the psychologist (University Rennes 2)
Study NCT02526342 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: V.A.C. UltraTM (KCI®,San Antonio, Texas, USA)
Description: Free muscle flaps are treated with Negative Pressure Wound Therapy (V.A.C. Ultra (KCI®,San Antonio, Texas, USA)) for five days following surgery with a continuous subatmospheric pressure of 125 mmHg.
Study NCT03015259 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide/Formoterol fumarate dihydrate
Description: Experimental: Treatment 1
Study NCT03015259 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Symbicort
Description: Active Comparator: Treatment 2
Study NCT03015259 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Comparator: Treatment 3
Study NCT03232086 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Clean Air
Description: Each subject will be exposed to clean air for 4 hours. Subjects will exercise on a bike or treadmill. Each exercise session will consist of a 15 minute exercise interval at a level of up to 25 L/min/m2BSA followed by a 15 minute rest period.
Study NCT03232086 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PM2.5
Description: Each subject will be exposed up to 35-50 μg/m3 PM2.5 for 4 hours. Subjects will exercise on a bike or treadmill. Each exercise session will consist of a 15 minute exercise interval at a level of up to 25 L/min/m2BSA followed by a 15 minute rest period.
Study NCT00143312 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: voriconazole
Description: Voriconazole is given to patients at least 48 hours after chemotherapy
Study NCT02244567 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin 850 mg twice daily for 3 months
Description: This drug is insulin sensitizing agent which will be given twice daily orally for 3 months for PCOS patients.
Study NCT02244567 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Serum uc-oc
Description: Serum uc-oc is a bone biomarker involved in incraesing insulin in pathophysiology of PCOS. It will be measured in serum of pcos patients before and after treatment with metformin for 3 months.
Study NCT02244567 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: drug
Description: This group of patients will receive any type of vitamin as a placebo to compare with effect of Metformin on serum UC-OC.